For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Orforglipron is Eli Lilly’s weight-loss pill, and Bank of America expects it to enter the market in the second half of 2026 ...

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

FDA may slap COVID-19 vaccines with “black box” warning; FDA to speed up process of Lilly’s oral pill; GSK CEO says the U.S. is the best country to invest in.

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...